Titan Pharmaceuticals, Inc. Deferred Sale Inducement Cost
Titan Pharmaceuticals, Inc. had Deferred Sale Inducement Cost of $20.00 million as of 2013-09-30, per its 10-Q filed 2013-11-14.
Discontinued › Notes
us-gaap:DeferredSalesInducementsNet · last filed 2013-11-14
- 2013-09-30: Deferred Sale Inducement Cost $20.00M.
- 2013-06-30: Deferred Sale Inducement Cost $16.70M.
- 2013-03-31: Deferred Sale Inducement Cost $17.80M.
- 2012-09-30: Deferred Sale Inducement Cost $15.30M.
| Period end | Deferred Sale Inducement Cost |
|---|---|
| 2013-09-30 | $20.00M 10-Q · filed 2013-11-14 |
| 2013-06-30 | $16.70M 10-Q · filed 2013-08-14 |
| 2013-03-31 | $17.80M 10-Q · filed 2013-05-15 |
| 2012-09-30 | $15.30M 10-Q · filed 2013-11-14 |
| 2012-06-30 | $17.00M 10-Q · filed 2013-08-14 |
| 2012-03-31 | $15.40M 10-Q · filed 2013-05-15 |
| 2011-09-30 | $12.20M 10-Q · filed 2012-11-09 |
| 2011-06-30 | $7.50M 10-Q · filed 2012-08-09 |